Jens Pedersen

Jens Pedersen

Auto-generated profile, based on publicly available information

Jens Pedersen

Department of Endocrinology and Internal Medicine, Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 December 2020 in Endocrinology
Verified
Journal Article
Closed access
PDF file
DADaniel B Andersen
Daniel B Andersen
KGKaare Villum Grunddal
Kaare Villum Grunddal
JPJens Pedersen
Jens Pedersen
RKRune E. Kuhre
Rune E. Kuhre
MLMari Lilith Lund
Mari Lilith Lund
CØCathrine Ørskov
Cathrine Ørskov
Glucagon-like peptide-1 receptor (GLP-1R) activation is used in the treatment of diabetes and obesity, however GLP-1 induces many other physiological effects with unclear mechanisms of action. To identify the cellular targets of GLP-1 and GLP-1 analogues, we generated a Glp1r.tdTomato reporter mouse expressing the reporter protein, tdTomato, in Glp1r expressing cells. The reporter signal is expressed in all cells where GLP-1R promoter was ever active. To complement this we histologically mapped tdTomato-fluorescence, and performed Glp-1r mRNA in situ hybridization and GLP-1R immunohistochemistry on the same tissues. In male mice, we found tdTomato-signal in mucous neck, chief-, and parietal cells of the stomach; Brunner’s glands; small intestinal enteroendocrine cells and intraepithelial lymphocytes; and myenteric plexus nerve fibers throughout the gastrointestinal tract. Pancreatic acinar-, β- and δ cells, but rarely α cells, were tdTomato-positive as were renal arteriolar smooth muscle cells; endothelial cells of the liver, portal vein and endocardium; aortal tunica media; and lung type 1 and 2-pneumocytes. Some thyroid follicular and parafollicular cells displayed tdTomato expression, as did tracheal cartilage chondrocytes, skin fibroblasts and sublingual gland mucous cells. In conclusion, our reporter mouse is a powerful tool for mapping known and novel sites of GLP-1R expression in the mouse, thus enhancing our understanding of the many target cells and effects of GLP-1 and GLP-1R agonists.

22 November 2022 in Communications Biology
Verified
Journal Article
Open access
PDF file
ABAnna Billeschou
Anna Billeschou
CJChristian Dall Johansen
Christian Dall Johansen
JCJens Bager Christensen
Jens Bager Christensen
SKSasha Alexandra Sampson Kjeldsen
Sasha Alexandra Sampson Kjeldsen
KGKatrine Douglas Galsgaard
Katrine Douglas Galsgaard
NANicolai Wewer Albrechtsen
Nicolai Wewer Albrechtsen
Glucagon is a major regulator of metabolism and drugs targeting the glucagon receptor (GCGR) are being developed. Insight into tissue and cell-specific expression of the GCGR is important to understand the biology of glucagon and to differentiate between direct and indirect actions of glucagon. However, it has been challenging to localize the GCGR in tissue due to low expression levels and lack of specific methods. Immunohistochemistry has frequently been used for GCGR localization, but antibodies targeting G-protein-coupled-receptors may be inaccurate. We evaluated all currently commercially available GCGR antibodies. The antibody, ab75240 (Antibody no. 11) was found to perform best among the twelve antibodies tested and using this antibody we found expression of the GCGR in the kidney, liver, preadipocytes, pancreas, and heart. Three antibody-independent approaches all confirmed the presence of the GCGR within the pancreas, liver and the kidneys. GCGR expression should be evaluated by both antibody and antibody-independent approaches.

1 June 2020 in American Journal of Physiology-Renal Physiology
Verified
Journal Article
Open access
PDF file
EJElisa P. Jensen
Elisa P. Jensen
SMSophie Møller
Sophie Møller
AHAleksander Vauvert Hviid
Aleksander Vauvert Hviid
SVSimon Veedfald
Simon Veedfald
Jens HolstJens Holst
Jens Holst
CSCharlotte M. Sørensen
Charlotte M. Sørensen
Glucagon-like peptide-1 (GLP-1) is an incretin hormone known to stimulate postprandial insulin release. However, GLP-1 also exerts extrapancreatic effects, including renal effects. Some of these renal effects are attenuated in hypertensive rats, where renal expression of GLP-1 receptors is reduced. Here, we assessed the expression and vascular function of GLP-1 receptors in kidneys from young prehypertensive rats. We also examined GLP-1-induced vasodilation in the renal vasculature in wild-type (WT) and GLP-1 receptor knockout mice using wire and pressure myography and the isolated perfused juxtamedullary nephron preparation. We investigated whether GLP-1 and the metabolite GLP-1(9–36)amide had renal vascular effects independent of the known GLP-1 receptor. We hypothesized that hypertension decreased expression of renal GLP-1 receptors. We also hypothesized that GLP-1-induced renal vasodilatation depended on expression of the known GLP-1 receptor. In contrast to normotensive rats, no immunohistochemical staining or vasodilatory function of GLP-1 receptors was found in kidneys from prehypertensive rats. In WT mice, GLP-1 induced renal vasodilation and reduced the renal autoregulatory response. The GLP-1 receptor antagonist exendin 9–39 inhibited relaxation, and GLP-1(9–36)amide had no vasodilatory effect. In GLP-1 receptor knockout mice, no relaxation induced by GLP-1 or GLP-1(9–36)amide was found, the autoregulatory response in afferent arterioles was normal, and no GLP-1-induced reduction of autoregulation was found. We conclude that in prehypertensive kidneys, expression and function of GLP-1 receptors is lost. The renal vasodilatory effect of GLP-1 is mediated exclusively by the known GLP-1 receptor. GLP-1(9–36)amide has no renal vasodilatory effect. GLP-1 attenuates renal autoregulation by reducing the myogenic response.

16 January 2024 in Journal of the Endocrine Society
Verified
Journal Article
Open access
PDF file
JPJens Pedersen
Jens Pedersen
AJAnne Elisabeth Jarløv
Anne Elisabeth Jarløv
ÅRÅse Krogh Rasmussen
Åse Krogh Rasmussen
KSKirstine Stochholm
Kirstine Stochholm
Objectives: Adrenocortical carcinoma (ACC) is a malignant tumor originating from the adrenal cortex. The aim of the study was to report the incidence of ACC and survival of ACC in Denmark. The secondary objective was to describe the impact of treatment with mitotane on survival. Design: Retrospective population study of patients diagnosed with ACC between 2003 and 2019 in Denmark. Methods: Individuals at risk for ACC were identified in the national Danish Health registries, and diagnosis of ACC was confirmed by review of the health records. Data on demographics, presentation, treatment, recurrence, and death was evaluated. Results: 138 patients were included in the study with more females (59.4%) than males (40.6%). Incidence rate was 1.4 per million per year. The incidence rate ratio significantly increased only in females by 1.06 [95% confidence interval (CI): 1.02-1.12] per year. Overall median survival was 1.93 (95% CI: 1.24-3.00) years with no differences between males and females. The proportion of patients treated with mitotane (either as adjuvant treatment or as part of a chemotherapeutic regime) was 72.3%. Survival was significantly decreased in women not treated with mitotane compared to women treated with mitotane (either as adjuvant or as part of a chemotherapeutic regime) hazards ratio .30 (95% CI: .10-.89), adjusted for European Network for the Study of Adrenal Tumours score, age at diagnosis, and year of diagnosis, but survival was unaffected by mitotane treatment in men. Conclusion: Incidence of ACC in Denmark was 1.4 per million per year and increased in women but not in males during the study period 2003-2019.

19 June 2023 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
PDF file
HGHannah Gilliam-Vigh
Hannah Gilliam-Vigh
TJTina Jorsal
Tina Jorsal
SNSophie W Nielsen
Sophie W Nielsen
JFJulie Forman
Julie Forman
JPJens Pedersen
Jens Pedersen
FKFilip Knop
Filip Knop
Background The hormone secretin (SCT) is released from intestinal S cells and acts via the SCT receptor (SCTR). Circulating SCT levels increase after Roux-en-Y gastric bypass surgery and have been associated with the massive weight loss and the high remission rates of type 2 diabetes (T2D) linked to these operations. Exogenous SCT was recently shown to reduce ad libitum food intake in healthy volunteers. To understand SCT biology and its potential role in T2D pathophysiology, we examined the intestinal mucosal expression profile of SCT and SCTR and evaluated the density of S cells along the intestinal tract of individuals with T2D and healthy controls. Methods Using immunohistochemistry and mRNA sequencing, we analyzed intestinal mucosa biopsies sampled along the small intestine at 30 cm intervals and from seven well-defined anatomical sites along the large intestine (during two sessions of double-balloon enteroscopy) in 12 individuals with T2D and 12 healthy controls. Results Both groups exhibited a progressive and similar decrease in SCT and SCTR mRNA expression and S cell density along the small intestine, with reductions of 14, 100, and 50 times, respectively, in the ileum compared to the duodenum (used as reference). Negligible amounts of SCTR and SCT mRNA, as well as a low S cell density, were found in the large intestine. No significant differences were observed between the groups. Conclusions SCT and SCTR mRNA expression and S cell density were abundant in the duodenum and decreased along the small intestine. Very low SCT and SCTR mRNA levels and S cell numbers were observed in the large intestine; without aberrations in individuals with T2D compared to healthy controls.

23 January 2026 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Closed access
AJAllan Jensen
Allan Jensen
MGMathilde Gottschau
Mathilde Gottschau
JCJane Christensen
Jane Christensen
SLSofie Lindquist
Sofie Lindquist
GAGitte Lerche Aalborg
Gitte Lerche Aalborg
SKSusanne K. Kjaer
Susanne K. Kjaer
Background: Prior research on the association between thyroid disease, ovarian cancer, and borderline ovarian tumors has been inconsistent. This nationwide cohort study investigated the risk of epithelial ovarian cancer and borderline ovarian tumors among 1,058,745 Danish women born between January 1, 1960, and December 31, 1997, and were followed until December 31, 2022, in relation to hypothyroidism and hyperthyroidism. Methods: Data on thyroid diagnoses, ovarian tumors, covariates, migration, and vital status were retrieved from Danish national registers. Hazard ratios (HR) and 95% confidence intervals (CI) for ovarian cancer and borderline ovarian tumors overall and for histologic subtypes were estimated using adjusted Cox proportional hazard models. A landmark analysis assessed ovarian tumor risk at age 60 years by thyroid disease status before age 40 years. Results: Over a median of 18.4 years of follow-up, 49,015 women developed hypothyroidism, 26,950 hyperthyroidism, 905 ovarian cancer, and 1,111 borderline ovarian tumors. No association was found between hypothyroidism and ovarian cancer (HR, 1.10; CI, 0.78–1.55) or borderline tumors (HR, 0.88; CI, 0.60–1.29). Hyperthyroidism was associated with increased rates of serous ovarian cancer (HR, 1.62; CI, 1–2.63) and borderline ovarian tumors (HR, 1.78; CI, 1.26–2.52), especially in postmenopausal and premenopausal women, respectively. However, absolute risk differences at age 60 years were small and not statistically significant. Conclusions: Hyperthyroidism may increase the rate of epithelial ovarian tumors, though clinical significance remains unclear, warranting further research. Impact: These findings indicate that hyperthyroidism may modestly influence epithelial ovarian tumor risk, underscoring the need to clarify shared biological mechanisms between thyroid and ovarian function.